Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Luye Pharm Leads $11.2 Million Funding of Chicago's Exicure

publication date: Nov 6, 2017

Exicure, a Chicago developer of nucleic acid drugs, closed a $11.2 million funding led by Yantai-based Luye Pharma. Exicure is developing gene silencing and immunotherapeutic drugs using its proprietary three-dimensional Spherical Nucleic Acid (SNA™) constructs to deliver the drug. So far, it has completed a small Phase I trial of a topical psoriasis treatment. Exicure, which previously received backing from Bill Gates and other tech leaders, has formed a $790 million collaboration/out-licensing agreement with Purdue Pharma for its lead psoriasis drug and three other targets. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.